FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial

April 30, 2026 02:56 PM EDT R&DFDA+ FDA's on­col­o­gy ad­vi­sors vote against 'new par­a­dig­m' in As­traZeneca breast can­cer tri­al Nicole DeFeudis Senior Reporter In its first meet­ing in about nine months, the FDA’s ad­vi­so­ry com­mit­tee of on­col­o­gy ex­perts vot­ed 6-3 Thurs­day that a late-stage tri­al for As­traZeneca’s oral … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER